Genetic correction of X-linked chronic granulomatous disease with novel foamy virus vectors

Experimental Hematology

Volumn 39, Issue 6, 2011, Pages 643-652

  Chatziandreou, Ilenia ^a   Siapati, Elena Konstantina ^a   Vassilopoulos, George ^a,b  

^a BRFAA   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; DIHYDRORHODAMINE; FOAMY VIRUS VECTOR; GLYCOPROTEIN GP 91; NITROBLUE TETRAZOLIUM; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RHODAMINE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL TRANSPLANTATION; CHIMERA; CHRONIC GRANULOMATOUS DISEASE; CONTROLLED STUDY; ENZYME ACTIVITY; EX VIVO STUDY; FEMALE; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; VIRAL GENE THERAPY; X CHROMOSOME LINKED DISORDER;

ANIMALS; BASE SEQUENCE; CELL LINE; DISEASE MODELS, ANIMAL; DNA PRIMERS; GENE THERAPY; GENETIC DISEASES, X-LINKED; GENETIC VECTORS; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; MICE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPUMAVIRUS; SUPEROXIDES;

HUMAN SPUMARETROVIRUS; MURINAE; MUS;

EID: 79956278622     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2011.03.003     Document Type: Article

References (39)

1. Kume A., Dinauer M.C. Gene therapy for chronic granulomatous disease. J Lab Clin Med 2000, 135:122-128.
2. Zhen L., King A.A., Xiao Y., Chanock S.J., Orkin S.H., Dinauer M.C. Gene targeting of X chromosome-linked chronic granulomatous disease locus in a human myeloid leukemia cell line and rescue by expression of recombinant gp91phox. Proc Natl Acad Sci U S A 1993, 90:9832-9836.
3. Kang E.M., Choi U., Theobald N., et al. Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. Blood 2010, 115:783-791.
4. Leung T., Chik K., Li C., Shing M., Yuen P. Bone marrow transplantation for chronic granulomatous disease: long-term follow-up and review of literature. Bone Marrow Transplant 1999, 24:567-570.
5. Seger R.A. Hematopoietic stem cell transplantation for chronic granulomatous disease. Immunol Allergy Clin North Am 2010, 30:195-208.
6. Mills E.L., Rholl K.S., Quie P.G. X-linked inheritance in females with chronic granulomatous disease. J Clin Invest 1980, 66:332-340.
7. Woodman R., Teoh D., Johnston F., et al. X-linked carriers of gp91-phox chronic granulomatous disease (CGD): clinical and potential therapeutic implications of extreme unbalanced X chromosome inactivation. Blood 1995, 86:27a.
8. Ott M.G., Schmidt M., Schwarzwaelder K., et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006, 12:401-409.
9. Stein S., Ott M.G., Schultze-Strasser S., et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010, 16:198-204.
10. Malech H.L., Maples P.B., Whiting-Theobald N., et al. Prolonged production of NADPH oxidase corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A 1997, 94. 22133-12138.
11. Malech H.L., Horwitz M.E., Linton G.F., et al. Extended production of oxidase normal neutrophils in X-linked chronic granulomatous disease following gene therapy with gp91phox transduced CD34+ cells. Blood 1998, 92:690.
12. Kang E., Malech H. Advances in treatment for chronic granulomatous disease. Immunol Res 2009, 43:77-84.
13. Moreno-Carranza B., Gentsch M., Stein S., et al. Transgene optimization significantly improves SIN vector titers, gp91phox expression and reconstitution of superoxide production in X-CGD cells. Gene Ther 2009, 16:111-118.
14. Hooks J.J., Gibbs C.J. The foamy viruses. Bacteriol Rev 1975, 39:169-185.
15. Falcone V., Schweizer M., Neumann-Haefelin D. Replication of primate foamy viruses in natural and experimental hosts. Curr Top Microbiol Immunol 2003, 277:161-180.
16. Rethwilm A. Foamy virus vectors: an awaited alternative to gammaretro- and lentiviral vectors. Curr Gene Ther 2007, 7:261-271.
17. Vassilopoulos G., Trobridge G., Josephson N.C., Russell D.W. Gene transfer into murine hematopoietic stem cells with helper-free foamy virus vectors. Blood 2001, 98:604-609.
18. Trobridge G.D., Miller D.G., Jacobs M.A., et al. Foamy virus vector integration sites in normal human cells. Proc Natl Acad Sci U S A 2006, 103:1498-1503.
19. Josephson N.C., Vassilopoulos G., Trobridge G.D., et al. Transduction of human NOD/SCID-repopulating cells with both lymphoid and myeloid potential by foamy virus vectors. Proc Natl Acad Sci U S A 2002, 99:8295-8300.
20. Josephson N.C., Trobridge G., Russell D.W. Transduction of long-term and mobilized peripheral blood-derived NOD/SCID repopulating cells by foamy virus vectors. Hum Gene Ther 2004, 15:87-92.
21. Andrianaki A., Siapati E.K., Hirata R.K., Russell D.W., Vassilopoulos G. Dual transgene expression by foamy virus vectors carrying an endogenous bidirectional promoter. Gene Ther 2010, 17:380-388.
22. Kiem H.P., Allen J., Trobridge G., et al. Foamy-virus-mediated gene transfer to canine repopulating cells. Blood 2007, 109:65-70.
23. Bauer T.R., Allen J.M., Hai M., et al. Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors. Nat Med 2008, 14:93-97.
24. Beard B.C., Keyser K.A., Trobridge G.D., et al. Unique integration profiles in a canine model of long-term repopulating cells transduced with gammaretrovirus, lentivirus, or foamy virus. Hum Gene Ther 2007, 18:423-434.
25. Nowrouzi A., Dittrich M., Klanke C., et al. Genome-wide mapping of foamy virus vector integrations into a human cell line. J Gen Virol 2006, 87:1339-1347.
26. Trobridge G., Josephson N., Vassilopoulos G., Mac J., Russell D.W. Improved foamy virus vectors with minimal viral sequences. Mol Ther 2002, 6:321-328.
27. Vassilopoulos G., Josephson N.C., Trobridge G. Development of foamy virus vectors. Methods Mol Med 2003, 76:545-564.
28. Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning: A Laboratory Manual 1989, Cold Spring Harbor Laboratory Press, Plainview, NY. 2nd ed.
29. Pollock J.D., Williams D.A., Gifford M.A., et al. Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production. Nat Genet 1995, 9:202-209.
30. Robert-Richard E., Ged C., Ortet J., et al. Human cell engraftment after busulfan or irradiation conditioning of NOD/SCID mice. Haematologica 2006, 91:1384-1387.
31. Wang L.J., Chen Y.M., George D., et al. Engraftment assessment in human and mouse liver tissue after sex-mismatched liver cell transplantation by real time quantitative PCR for Y chromosome sequences. Liver Transpl 2002, 8:822-828.
32. Brenner S., Whiting-Theobald N.L., Linton G.F., et al. Concentrated RD114-pseudotyped MFGS-gp91phox vector achieves high levels of functional correction of the chronic granulomatous disease oxidase defect in NOD/SCID/beta -microglobulin-/- repopulating mobilized human peripheral blood CD34+ cells. Blood 2003, 102:2789-2797.
33. Vassilopoulos G., Rethwilm A. The usefulness of a perfect parasite. Gene Ther 2008, 15:1299-1301.
34. Goebel W.S., Pech N.K., Dinauer M.C. Stable long-term gene correction with low-dose radiation conditioning in murine X-linked chronic granulomatous disease. Blood Cells Mol Dis 2004, 33:365-371.
35. Ding C., Kume A., Björgvinsdóttir H., Hawley R.G., Pech N., Dinauer M.C. High-level reconstitution of respiratory burst activity in a human X-linked chronic granulomatous disease (X-CGD) cell line and correction of murine X-CGD bone marrow cells by retroviral-mediated gene transfer of human gp91phox. Blood 1996, 88:1834-1840.
36. Björgvinsdóttir H., Ding C., Pech N., Gifford M.A., Li L.L., Dinauer M.C. Retroviral-mediated gene transfer of gp91phox into bone marrow cells rescues defect in host defense against Aspergillusfumigatus in murine X-linked chronic granulomatous disease. Blood 1997, 89:41-48.
37. Dinauer M.C., Li L.L., Björgvinsdóttir H., Ding C., Pech N. Long-term correction of phagocyte NADPH oxidase activity by retroviral-mediated gene transfer in murine X-linked chronic granulomatous disease. Blood 1999, 94:914-922.
38. Sadat M.A., Pech N., Saulnier S., et al. Long-term high-level reconstitution of NADPH oxidase activity in murine X-linked chronic granulomatous disease using a bicistronic vector expressing gp91phox and a Delta LNGFR cell surface marker. Hum Gene Ther 2003, 14:651-666.
39. Goldblatt D., Thrasher A.J. Chronic granulomatous disease. Clin Exp Immunol 2000, 122:1-9.